Salarius Pharmaceuticals, Inc.

NasdaqCM:SLRX Stok Raporu

Piyasa değeri: US$2.1m

Salarius Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 3/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

David Arthur

İcra Kurulu Başkanı

US$355.7k

Toplam tazminat

CEO maaş yüzdesi92.8%
CEO görev süresi5.3yrs
CEO sahipliği0.4%
Yönetim ortalama görev süresiVeri yok
Yönetim Kurulu ortalama görev süresi5.3yrs

Son yönetim güncellemeleri

Recent updates

Salarius pharmaceuticals announces 1-for-25 reverse stock split

Oct 14

Salarius adds 12% after updates on clinical programs and financials

Sep 13

Salarius Pharma adds two Mayo Clinic sites to phase 1/2 trial of Seclidemstat as treatment for cancers

Aug 22

Salarius Pharmaceuticals GAAP EPS of -$0.09 beats by $0.01

Aug 08

Salarius Pharmaceuticals and VolitionRx enter into R&D collaboration agreement

Aug 02

Salarius Pharma reports new seclidemstat results in Ewing sarcoma and other solid tumors at ASCO21

Jun 07

Salarius Pharmaceuticals (SLRX) Investor Presentation - Slideshow

May 27

Salarius Pharmaceuticals (NASDAQ:SLRX) Shareholders Have Enjoyed An Impressive 155% Share Price Gain

Feb 09
Salarius Pharmaceuticals (NASDAQ:SLRX) Shareholders Have Enjoyed An Impressive 155% Share Price Gain

Salarius Pharmaceuticals receives second installment of $1.7M in payments

Jan 13

Salarius Pharma raises $3.5M via warrant exercise

Dec 11

Salarius Pharmaceuticals EPS in-line, beats on revenue

Nov 11

CEO Tazminat Analizi

David Arthur'un ücretlendirmesi Salarius Pharmaceuticals'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024n/an/a

-US$6m

Mar 31 2024n/an/a

-US$9m

Dec 31 2023US$356kUS$330k

-US$13m

Sep 30 2023n/an/a

-US$18m

Jun 30 2023n/an/a

-US$30m

Mar 31 2023n/an/a

-US$31m

Dec 31 2022US$941kUS$500k

-US$32m

Sep 30 2022n/an/a

-US$29m

Jun 30 2022n/an/a

-US$19m

Mar 31 2022n/an/a

-US$17m

Dec 31 2021US$677kUS$379k

-US$13m

Sep 30 2021n/an/a

-US$11m

Jun 30 2021n/an/a

-US$9m

Mar 31 2021n/an/a

-US$8m

Dec 31 2020US$1mUS$340k

-US$8m

Sep 30 2020n/an/a

-US$7m

Jun 30 2020n/an/a

-US$8m

Mar 31 2020n/an/a

-US$7m

Dec 31 2019US$518kUS$315k

-US$7m

Sep 30 2019n/an/a

-US$6m

Jun 30 2019n/an/a

-US$4m

Mar 31 2019n/an/a

-US$3m

Dec 31 2018US$275kUS$258k

-US$2m

Tazminat ve Piyasa: David 'nin toplam tazminatı ($USD 355.70K ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 651.15K ).

Tazminat ve Kazançlar: David 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.


CEO

David Arthur (61 yo)

5.3yrs

Görev süresi

US$355,700

Tazminat

Mr. David J. Arthur, M.B.A., has been President at Salarius Pharmaceuticals, Inc since July 19, 2019 and Chief Executive Officer & Director at Salarius Pharmaceuticals, Inc. since July 2019. Mr. Arthur ser...


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
David Arthur
CEO, President & Director5.3yrsUS$355.70k0.43%
$ 9.0k
Jonathan Lieber
Independent Director4.4yrsUS$53.76k0.026%
$ 541.1
Bruce McCreedy
Independent Director5.3yrsUS$45.26k0.012%
$ 264.6
Arnold Hanish
Independent Director5.3yrsUS$67.26k0.029%
$ 605.7
William McVicar
Chairman of the Board5.3yrsUS$82.26k0.025%
$ 523.3
Tess Burleson
Independent Director5.3yrsUS$64.76k0.024%
$ 499.8

5.3yrs

Ortalama Görev Süresi

63yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: SLRX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.3 yıldır).